Optimization and chemical biology of novel antifungals to combat azole resistant mould infections

Active Project Grant Awarded Last action

Award ID
R01AI181215
Recipient
Awarding agency
Obligated
$3,834,833

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 53% complete
Place of performance
Hanover, NH 03755, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The filamentous fungi, or moulds, present a particularly daunting clinical challenge with high treatment failure rates and intrinsic and/or emerging multi-drug resistance. Currently, only 3 classes of antifungal drugs are utilized to treat the majority of human fungal infections. We aim to address this significant and growing human health problem by developing a nonspirocyclic piperidine series (NSP) series of small molecules with potent antifungal activity that can overcome mould specific antifungal drug resistance in the complex infection microenvironment. The NSP series was discovered using a high-throughput small molecule antifungal screen under low oxygen conditions and in the presence or absence of fluconazole with the most common mould human pathogen aspergillus fumigatus. From this novel screen, we identified MBX-7591, a NSP family small molecule with drug-like properties that displayed potent antifungal activity that is potentiated under low oxygen conditions. MBX-7591 also potentiates the antifungal activity of fluconazole and other triazoles against a. Fumigatus, which is intrinsically fluconazole resistant. The combination of MBX-7591 and voriconazole is highly active against azole resistant a. Fumigatus isolates. Additional studies revealed that MBX-7591 has potent antifungal activity against multiple drug resistant mould species including agents of mucormycoses rhizopus arrhizus and mucor circinelloides. Pilot murine invasive pulmonary aspergillosis model studies reveal a promising safety profile and in vivo efficacy. Based on these exciting results, our premise is that MBX-7591 analogs represent a promising new generation of safe and in vivo efficacious small molecules to combat the growing emergence of drug resistant human fungal infections. In aim 1, we will utilize SAR-driven chemical optimization of the NSP series to synthesize 300 analogs with key drug-like properties such as solubility. In aim 2, we will evaluate and prioritize NSP analogs in SAR-driving in vitro assays for potency, selectivity, and adme properties with the goal of identifying 5-10 analogs with potent mics against a. Fumigatus, R. Arrhizus, and M. Circinelloides. In aim 3, we will utilize genetic, biochemical, and chemical biology approaches to define the molecular target of MBX-7591 and key analogs. In aim 4, we will identify a lead NSP compound and backup based on tolerability, pharmacokinetic parameters, and efficacy in murine models of invasive mould infections. Taken together, our proposed studies will further develop an exciting novel small molecule with infection microenvironment activity against a spectrum of clinically challenging pathogenic moulds.

Transactions

Action Obligated Date
Amendment $767,843
Amendment $767,555
Amendment $49,751
Amendment $49,751
Amendment $733,311
Amendment $733,311
Original award $733,311

Subawards

Subrecipient Amount Awarded
Microbiotix, Inc. Optimization and chemical biology of novel antifungals to combat azole resistant mould infections $1,024,366

Quick answers

Who received award R01AI181215?

R01AI181215 was awarded to Trustees Of Dartmouth College by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 1, 2024.

How much is award R01AI181215 worth?

$3,834,833 has been obligated on R01AI181215.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login